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Abstract Colorectal adenomas form a biologically and
clinically distinct intermediate stage in development of
colorectal cancer (CRC) from normal colon epithelium.
Only 5% of adenomas progress into adenocarcinomas,
indicating that malignant transformation requires other
biological alterations than those involved in adenoma
formation. The present study aimed to explore which
cancer-related biological processes are affected during
colorectal adenoma-to-carcinoma progression and to iden-
tify key genes within these pathways that can serve as
tumor markers for malignant transformation. The activity of
12 cancer-related biological processes was compared
between 37 colorectal adenomas and 31 adenocarcinomas,
using the pathway analysis tool Gene Set Enrichment
Analysis. Expression of six gene sets was significantly
increased in CRCs compared to adenomas, representing
chromosomal instability, proliferation, differentiation, inva-
sion, stroma activation, and angiogenesis. In addition, 18
key genes were identified for these processes based on their
significantly increased expression levels. For AURKA and
PDGFRB, increased mRNA expression levels were verified
at the protein level by immunohistochemical analysis of a
series of adenomas and CRCs. This study revealed cancer-
related biological processes whose activities are increased
during malignant transformation and identified key genes
which may be used as tumor markers to improve molecular
characterization of colorectal tumors.
Keywords Colorectal cancer . Adenoma-to-carcinoma
progression . Pathway analysis . Tumor markers
Introduction
Colorectal cancer (CRC) is the second leading cause of
cancer mortality in the western world. CRC develops from
normal colon epithelium through an adenoma precursor
stage. Premalignant colon adenomas arise by disruption of
the Wnt-signaling pathway, mostly by DNA mutations in,
or (epigenetic) silencing of the APC tumor suppressor gene
[1]. Additional mutations in genes like KRAS and P53, as
well as specific chromosome copy number changes like 20q
gain, further contribute to adenoma-to-carcinoma progres-
sion [2, 3]. It is estimated that only a small proportion of
about 5% of adenomas will advance to the clinically more
relevant stage of CRC, implying that the biology of
adenoma formation from normal colon epithelium differs
significantly from that of malignant transformation of
colorectal adenomas into adenocarcinomas.
Biological processes that are frequently altered during
carcinogenesis affect the behavior of tumor cells and
tissues. Tumor cells exhibit increased proliferation and lack
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of apoptosis, overcome senescence, and may gain invasive
and metastatic potential [4]. Expanding tumors become
hypoxic and induce angiogenesis, while sustained angio-
genesis results in poor vasculature and contributes to
activation of stroma by serum exposure (wound response)
[4, 5]. Moreover, effective immune responses are circum-
vented or avoided, for instance by forcing tumor-associated
macrophages to generate an immune suppressive microen-
vironment [6]. Accumulation of (epi)genetic aberrations
leads to changes in gene expression and affect the activity
of cancer-related pathways. Microarray mRNA expression
studies allow to compare gene expression at a genome-wide
level and to explore the transcriptional programs that are
turned on or off in tumors during progression from normal
through premalignant stages to cancer. However, extracting
such complex information from large datasets derived from
heterogeneous biological samples has proven to be difficult.
Pathway analysis programs such as Gene Set Enrichment
Analysis (GSEA) can be of help here [7]. GSEA makes use
of the fact that changes in biological characteristics require
coordinate variation in expression of groups of genes, i.e.,
gene sets, which regulate biological activity. While absolute
changes in expression levels of the majority of individual
genes are often modest to small and do not reach statistical
significance, GSEA allows to estimate groupwise variation
in expression of predefined gene sets, indicative for
pathway activity levels.
The concept that cancer development is the result of
defects in multiple biological processes, e.g., as described
by Hanahan and Weinberg, is well accepted [4]. The
present study aims to examine the changes in the activity
of these cancer-related biological processes during malig-
nant transformation of colorectal adenomas into adenocar-
cinomas. We here report careful composition of predefined
gene sets that represent various aspects of carcinogenesis
and application of the GSEA pathway analysis program to
compare their activity levels in benign and malignant
colorectal lesions. Moreover, individual genes that differed
most significantly within the respective pathways were
identified.
Materials and methods
Microarray mRNA expression profiling of colorectal
tumor tissue samples
Genomewide mRNA expression data were obtained by
microarray analysis of 37 colorectal adenomas and 31
adenocarcinomas, as described previously [8]. The micro-
array expression data can be accessed through the Gene
Expression Omnibus under accession number GSE8067
(http://www.ncbi.nlm.nih.gov/geo/). Genes with missing
values in more than 20% of tumor samples were excluded
from further analysis. Remaining missing values were
imputed using k-nearest neighbor averaging, as imple-
mented in the R-package “impute” [9].
Selection of gene sets representing cancer-related processes
The pathway analysis tool GSEA makes use of predefined
gene sets. We aimed to examine which carcinogenic
processes could be relevant to adenoma-to-carcinoma
progression and, therefore, restricted GSEA analysis to
carefully selected cancer-related gene sets. Cancer-related
processes explored comprised: proliferation, cell cycle,
apoptosis, tumor differentiation, tumor cell invasion,
metastasis, chromosomal instability, and microenvironmen-
tal changes such as hypoxia, angiogenesis, immune
response, tumor-associated macrophages, and tumor stroma
activation. On the one hand, Gene Ontology (GO) terms
were used to obtain gene sets from the NCBI Entrez Gene
database. The following keywords yielded GO-derived
gene sets: proliferation, apoptosis, cell cycle, differentia-
tion, hypoxia, angiogenesis, and immune response. On the
other hand, gene sets were collected of which altered
coordinated expression in cancer had been observed in an
experimental setting, by searching the NCBI PubMed
database. Cancer-related experiment-derived gene sets
included: proliferation [10], tumor differentiation [11],
invasion [12], metastasis [13], chromosomal instability
[14], hypoxia [15], angiogenesis [16], tumor-associated
macrophages [17], and stroma activation [18]. Together,
seven GO-derived gene sets and nine experiment-derived
gene sets were selected for pathway analysis by GSEA. The
total number of genes within each gene set and the number
of genes covered by the microarray expression data are
listed in Table 1. A complete list of genes within the 16
gene sets is provided in Supplementary Table 1. Supple-
mentary Table 2 gives detailed information about the origin
of the gene sets.
GSEA pathway analysis of gene expression
Pathway analysis of gene expression was performed using
GSEA (v2.0, http://www.broad.mit.edu/gsea/) [7]. GSEA
performs a competitive analysis of predefined gene sets,
which is suited for examination of relatively heterogeneous
biological samples. In brief, GSEA first ranks all genes
analyzed by expression arrays according to their differential
expression between two categories of samples, in this case,
colorectal adenomas and carcinomas. Next, for each
predefined gene set analyzed, GSEA calculates a pathway
enrichment score that indicates to what extent these gene
sets are enriched for the highest—(or lowest)—ranking
genes. Default settings were used, except for the maximum
90 Tumor Biol. (2010) 31:89–96
size of gene sets, which was set to 1,500 to include all
predefined gene sets for analysis. Thresholds for signifi-
cance of the enrichment score were determined by
permutation analysis (1,000 permutations). False discovery
rate (FDR) q values<0.05 were considered significant.
Identification of key genes for pathway activity
Individual genes from cancer-related gene sets for which
mRNA expression levels differed most between colorectal
adenomas and CRCs, were considered key genes for
pathway activity. For individual genes within cancer-
related gene sets that contributed to the enrichment score,
p values were calculated using the Student’s t test with
unequal variance. P values<1e-5 (uncorrected for multiple
testing) were considered significant.
Immunohistochemistry analysis of AURKA and PDGFRB
Immunohistochemical staining of aurora kinase A
(AURKA) and platelet-derived growth factor receptor beta
(PDGFRB) was performed on 4-μm thick paraffin sections
of a series of nine colorectal adenomas and 10 adenocarci-
nomas. Sections were deparaffinized in xylene and rehy-
drated through a series of graded alcohol to water.
Endogenous peroxidase was blocked with hydrogen perox-
ide (0.3% H2O2 in methanol) for 30 min. Antigen retrieval
was performed by autoclave heating in 10 mM citrate
buffer (pH6.0). Antibodies directed against AURKA
(mouse monoclonal NCL-L-AK2, Novocastra Laboratories,
Newcastle upon Tyne, UK) or PDGFRB (rabbit polyclonal
28E1, Cell Signaling Technology, Danvers, USA) were
incubated overnight at 4°C (1:50 dilution). AURKA
staining was visualized using the Dako EnVision Kit-
K4006 (Dako Cytomation, Copenhagen, Denmark) and
PDGFRB staining using the PowerVision+ Kit (Immuno-
Logic, Duiven, NL) according to the manufacturer’s
recommendations. Sections were counterstained with
Mayer's hematoxylin. Incubation without primary antibody
was used as negative control.
Results
GSEA pathway analysis of colorectal adenomas and CRCs
Six cancer-related gene sets showed increased expression in
CRCs compared to adenomas (FDR<0.05), i.e., chromosomal
instability, proliferation, differentiation, angiogenesis, stroma
activation, and invasion (Table 1). Of these, the change in
activity of the chromosomal instability gene set was most
significant (FDR=0.004).
Identification of key genes for pathway activity
in adenoma-to-carcinoma progression
While the far majority of individual genes within the six
gene sets involved in adenoma-to-carcinoma progression
will exhibit modest, nonsignificant variation in gene
expression between colorectal adenomas and adenocarci-
nomas, specific genes within these gene sets that do show
large variation in mRNA expression levels may function as
key genes for the activity of cancer-related pathways
involved in malignant transformation. To identify such
genes from the six differentially expressed cancer-related
gene sets, individual genes were ranked according to their
difference in mRNA expression between 37 colorectal
adenomas and 31 CRCs. P values<1e-5 were considered
significant at the genome-wide level. This procedure
yielded key genes for five out of six biological processes:
AURKA, C20orf24, and TPX2 (chromosomal instability);
PLK1 and CCNF (proliferation); ADRM1 and NUDT1
(differentiation); SSSCA1, ID3, LUM, FYCO1, RFC3,
LOXL2 , SVIL , KIAA0367 , and NUDT1 (stroma
Table 1 GSEA comparison of the activity of cancer-related gene-sets
in colorectal adenomas and CRCs
Cancer-related process, GO- or
Exp-derived gene set
Genes analyzed/
size gene seta
GSEA FDR
q value
Chromosomal instability (Exp) 66/71 0.004
Proliferation (GO) 639/680 0.254
Proliferation (Exp) 41/45 0.036
Apoptosis (GO) 549/584 0.515
Cell cycle (GO) 669/722 0.052
Differentiation (GO) 611/667 0.247
Differentiation (Exp) 66/69 0.043
Hypoxia (GO) 18/21 0.128
Hypoxia (Exp) 80/85 0.224
Angiogenesis (GO) 95/100 0.043
Angiogenesis (Exp) 55/61 0.850
Immune response (GO) 468/565 0.301
Tumor-associated macrophages
(Exp)
56/59 0.058
Stroma activation (Exp) 258/276 0.032
Invasion (Exp) 93/97 0.034
Metastasis (Exp) 56/59 0.282
Pathway analysis using GSEA was performed on a genome-wide
microarray expression profile of 37 colorectal adenomas and 31
adenocarcinomas. Listed are the cancer-related gene sets analyzed, the
number of genes covered by the microarray relative to the gene set
size and the FDR q value obtained by GSEA analysis. FDR q values<
0.05 (in bold) were considered significant
a Some genes could not be analyzed, either due to technical problems
(missing values in more than 20% of the samples) or because they
were not represented on the microarray
GO gene ontology, Exp experiment
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activation); and SPARC, DCN, and PDGFRB (invasion).
For the angiogenesis gene set, none of the individual genes
passed the threshold for genome-wide significance. Table 2
lists all genes within the cancer-related processes that
exhibited p values<1e-4. The magnitude of differential
expression between colorectal adenomas and adenocarci-
nomas for genes from each of these processes, i.e., AURKA,
PLK1, ADRM1, SSSCA1, SPARC, and PDGFRB, is
illustrated with boxplots (Fig. 1).
AURKA and PDGFRB protein expression in adenomas
and CRCs
Most of the key genes for pathways involved in malignant
transformation have previously been described to play a
role in carcinogenesis, and some of them are considered
potential cancer drug targets. For two such key genes for
which good antibodies were available, AURKA (chromo-
somal instability gene set) and PDGFRB (invasion gene
set), we aimed to validate their difference in mRNA
expression between colorectal adenomas and CRCs at the
protein level. Immunohistochemical stainings were per-
formed on a series of nine colorectal adenomas and 10
adenocarcinomas. Four adenomas stained negative for
AURKA, another four were weakly positive, while strong
staining was observed in only one adenoma. In contrast,
only two CRCs stained negative for AURKA, weak
staining was observed for four CRCs, while strong
AURKA expression was observed in the epithelial cells of
four CRCs, consistent with previous observations [8]. For
PDGFRB, staining was nearly absent in six out of nine
adenomas, while three adenomas stained weakly positive.
In contrast, PDGFRB protein expression was observed in
the stromal compartment of nine out of 10 CRCs, four of
which stained weakly positive and five of which stained
strongly positive. Representative images for AURKA and
PDGFRB staining are given in Fig. 2.
Discussion
Colorectal adenoma formation and further progression into
carcinomas is caused by accumulation of (epi)genetic
alterations. As such, one might expect colorectal carcino-
genesis to be a stochastic process in which, sooner or later,
malignant progression is an inevitable event. However,
biologically and clinically, colorectal adenomas form a
distinct intermediate stage in CRC development from
normal colon epithelium. It is estimated that only 5% of
adenomas ever progress into adenocarcinomas, indicating
that carcinoma formation from adenomas requires signifi-
cantly different biological and, therefore, molecular alter-
ations than those involved in adenoma formation from
Table 2 Key genes in cancer-related processes associated with
colorectal adenoma-to-carcinoma progression
Cancer-related process,
GO- or Exp-derived gene set
Gene symbol p Value (Student’s
t test with unequal
variance)
Chromosomal instability (Exp) AURKA 3.58 e-09
C20orf24 1.15 e-07
TPX2 2.60 e-06
TRIP13 1.32 e-05
ATAD2 1.80 e-05
CDCA3 1.88 e-05
UBE2C 2.55 e-05
CDC45L 6.40 e-05
AURKB 6.64 e-05
NEK2 6.95 e-05
NXT1 7.91 e-05
ASF1B 8.52 e-05
Proliferation (Exp) PLK1 5.93 e-06
CCNF 7.46 e-06
DNMT1 1.81 e-05
PKMYT1 3.00 e-05
AURKB 6.64 e-05
Differentiation (Exp) ADRM1 8.42 e-07
NUDT1 9.57 e-06
CENPA 1.05 e-05
TRIP13 1.32 e-05
UBE2C 2.55 e-05
MYBL2 5.62 e-05
Angiogenesis (GO) EREG 1.28 e-05
COL15A1 1.75 e-05
SERPINE1 9.07 e-05
Stroma activation (Exp) SSSCA1 9.25 e-09
ID3 1.09 e-08
LUM 5.69 e-08
FYCO1 2.63 e-07
RFC3 6.27 e-07
LOXL2 6.80 e-07
SVIL 1.50 e-06
KIAA0367 6.37 e-06
NUDT1 9.57 e-06
MYBL2 5.62 e-05
TAGLN 7.31 e-05
Invasion (Exp) SPARC 7.82 e-08
DCN 8.04 e-07
PDGFRB 3.96 e-06
INHBA 4.40 e-05
TNC 7.20 e-05
Within the six differentially expressed cancer-related processes
involved in adenoma-to-carcinoma progression, genes that contribute
to the GSEA pathway enrichment score were ranked according to the
difference in mRNA expression between adenomas and CRCs
(p values). Genes with a p value<1e-5 were considered significant
at the genome-wide level and selected as key genes within pathways
(in bold). Listed are the genes that exhibit p values<1e-4
GO gene ontology, Exp experiment
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normal epithelium. Given the high prevalence of colorectal
adenomas and the relatively low progression rate, one could
argue that especially biological processes involved in
adenoma-to-carcinoma progression are most relevant from
a clinical point of view. We here report identification of six
cancer-related biological processes whose activity is in-
creased in CRCs compared to adenomas (Table 1) and a list
of key genes whose increased mRNA expression levels are
associated with malignant transformation (Table 2). For two
of these genes, i.e., AURKA and PDGFRB, differential
expression was verified at the protein level (Fig. 2).
The GSEA carcinogenic pathway analysis performed in
the present study was restricted to a limited number of 16
carefully selected cancer-related gene sets for two reasons.
First, although large databases that contain numerous
predefined gene sets are available, such as the Molecular
Signatures Database (www.broad.mit.edu/gsea/msigdb),
none of these contain a well-defined subset of gene sets
representing various biological aspects of carcinogenesis.
Second, it is not recommended to perform GSEA using
large groups of gene sets that are not relevant to the
research question addressed, as this will increase the
multiple testing problem and lead to unnecessary decrease
of statistical power. Therefore, we set out to select gene sets
representing cancer-related processes using two strategies,
one based on Gene Ontology terms (seven gene sets) and
one based on a PubMed literature search of in vitro and in
vivo experimental data (nine gene sets). For four cancer-
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Fig. 1 Comparison of mRNA expression levels for key genes of
pathway activity in colorectal adenomas and CRCs. Boxplots showing
mRNA expression levels of 37 colorectal adenomas and 31 colorectal
adenocarcinomas, based on oligonucleotide microarray expression
data. Expression of key genes was significantly higher in CRC
compared to adenomas (p values<1e-5). a AURKA; b PLK1; c
ADRM1; d SSSCA1; e SPARC; and f PDGFRB
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related processes (proliferation, differentiation, hypoxia,
and angiogenesis) gene sets were obtained using both
strategies, allowing to compare their value for GSEA
carcinogenic pathway analysis. The experiment-derived
“proliferation” and “differentiation” gene sets yielded a
significant difference between adenomas and CRCs while
their GO-derived equivalents did not. In contrast, the GO-
derived “angiogenesis” gene set yielded a significant
difference while the experiment-derived gene set did not.
No significant differences were observed at all for the
experiment- and GO-derived “hypoxia” gene sets. These
data illustrate that both strategies revealed useful gene sets
for GSEA carcinogenic pathway analysis. However, they
also imply that optimal gene sets may not be available yet
for all (colorectal) cancer-related processes.
The GSEA carcinogenic pathway analysis results indi-
cated significantly different rates of chromosomal instabil-
ity, proliferation, differentiation, angiogenesis, stroma
activation, and invasion between colorectal adenomas and
CRCs (Table 1). These results fit current knowledge about
malignant transformation. Chromosomal instability
increases the rate of genomic alterations, necessary to
bypass the rate-limiting steps in carcinogenesis [19].
Analysis of chromosome copy number changes by com-
parative genomic hybridization has demonstrated that
CRCs exhibit much more chromosomal instability than
adenomas [3, 8]. The present data show that the chromo-
somal instability gene set changes highly significantly in
activity during adenoma-to-carcinoma progression. This
further emphasizes the importance of chromosomal insta-
bility in colorectal adenoma-to-carcinoma progression.
Chromosomal instability might even be the driving force
in tumor progression by initiating the changes in other
cancer-related biological processes. Although the balance
between proliferation and differentiation is already abnor-
mal in adenomas, proliferation rates further increase during
the adenoma–carcinoma sequence [20]. Angiogenesis is
induced by growing tumors in an attempt to meet their
increasing demand for oxygen and nutrients. Microvessel
density, a widely used surrogate marker for angiogenesis,
has been shown to be increased in CRCs compared to
colorectal adenomas [21]. In comparison to adenomas,
CRCs also contain much more tumor stroma, which is often
composed of reactive tissue that resembles wounds that do
not heal [5]. Interestingly, the amount of stroma differs
widely among CRCs [22], and a high stroma percentage has
been correlated with poor prognosis in CRC patients [23].
Hence, increased expression of the invasion gene set by
CRCs fits the concept of adenoma-to-carcinoma progression.
For several cancer-related processes, no significant
differences were revealed between adenomas and CRCs,
i.e., for gene sets representing apoptosis, cell cycle,
hypoxia, immune response, tumor-associated macrophages,
and metastasis. One interpretation is that these biological
Fig. 2 Comparison of protein
expression levels for AURKA
and PDGFRB in colorectal
adenomas and CRCs. Immuno-
histochemical stainings for
AURKA and PDGFRB
confirmed overexpression of
both proteins in CRCs compared
to colorectal adenomas.
AURKA staining can be found
in the epithelial cells, while
PDGFRB expression is
observed in tumor stroma.
Representative examples of
AURKA and PDGFRB staining
are shown for colorectal
adenoma and carcinoma tissue.
Digital images were obtained
with a 20× objective (AURKA)
and a 10× objective (PDGFRB)
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processes are more relevant during formation of colorectal
adenomas from normal colon epithelium, than during
adenoma-to-carcinoma progression. Alternatively, although
these biological processes could play a role in malignant
transformation, the selected gene sets may not adequately
represent the in vivo situation analyzed here. For instance,
GO-derived gene sets are composed of groups of genes
known to be involved in similar biological processes,
irrespective of whether they actually function in a coordi-
nated manner or not. In contrast, experiment-derived gene
sets are composed of groups of genes that are coordinately
expressed during certain biological processes; however,
assumptions have been made about conservation of these
gene sets across species, across tumor types and about the
validity of extrapolation from in vitro to in vivo settings.
Nevertheless, although our approach may underestimate the
effects of some cancer-related processes in adenoma-to-
carcinoma progression, the positively identified gene sets
yield valuable information for further investigation, such as
the identification of key genes for malignant transforma-
tion. Expression of individual genes within gene sets that
were positively identified by GSEA yielded a list of these
key genes for various carcinogenic processes that may be
used for molecular characterization of series of tumor
samples (Table 2). Some of these genes have been
described to contribute to (colorectal) carcinogenesis. From
the “chromosomal instability” gene set, AURKA and TPX2
(targeting protein for XKLP2) have been reported to
interact with each other and to play a role in centrosome
maturation and spindle formation [24]. Aberrant expression
of TPX2 has been reported in breast, endometrial, and lung
cancer and in neuroblastoma [25]. Furthermore, TPX2
overexpression at the protein level was found to be
associated with poor prognosis in lung cancer [25].
AURKA, when overexpressed, induces centrosome amplifi-
cation, aneuploidy, and cellular transformation in vitro [26].
In nasopharyngeal carcinoma, AURKA overexpression was
correlated with clinical stage and invasiveness, and inhibi-
tion with small molecules or RNA interference reduced cell
invasion in vitro [27]. From the “proliferation” gene set,
polo-like kinase 1 (PLK1) is thought to play a role in
spindle formation and in cell cycle progression during the
G2 and M phase [28]. Interference with PLK1 expression
decreases proliferation, induces apoptosis, and affects
spindle assembly in vitro [29]. Moreover, down-
modulation of PLK1 expression was found to inhibit
growth of bladder cancer in mice [29]. Expression of
PLK1 and CCNF (cyclin F), which contributes to the G2 to
M phase transition, have been related to response to radio
and chemotherapy [30, 31]. From the “invasion” gene set,
secreted protein acidic and rich in cysteine (SPARC) (also
known as osteonectin) is overexpressed in CRCs and
induces proinvasive activity [32]. PDGFRB is upregulated
within CRC tumor stroma, and blocking of PDGFRB
signaling has been shown to inhibit colon tumor growth
and metastasis [33].
Immunohistochemical analysis of a series of colorectal
adenomas and adenocarcinomas was used to verify the
expression of some of the key genes at the protein level, i.e.,
AURKA and PDGFRB (Fig. 2). CRCs exhibited more
frequently more intense staining for both proteins than
adenoma tissue. Therefore, both AURKA and PDGFRB
may have the potential to be used as markers indicative for
the activity level of “chromosomal instability” and “inva-
sion,” respectively. For AURKA, protein staining was
restricted to epithelial cells, indicating that AURKA influen-
ces CRC progression by its effect on tumor cells. PDGFRB
staining was predominantly observed within tumor stroma,
suggesting a stromal effect of PDGFRB on cancer progres-
sion. In this way, information on protein expression helps to
put mRNA expression data into biological context.
In summary, GSEA was applied as a tool for pathway
analysis of gene expression using a restricted number of
gene sets representing cancer-related biological processes.
Expression of six gene sets was increased in CRCs
compared to adenomas, of which the chromosomal insta-
bility pathway was most prominent. Subsequently, key
genes within these gene sets that exhibited significant
differential expression were identified. Further research is
required to explore whether these genes can be used as
tumor markers for malignant transformation, and/or as drug
targets for distinct carcinogenic pathways that contribute to
colorectal adenoma-to-carcinoma progression.
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